8-K 1 caodeparts.htm 8-K CAO Departs


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 21, 2014

NxSTAGE MEDICAL, INC.
(Exact name of registrant as specified in its charter)

Delaware
000-51567
04-3454702
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
 
 
350 Merrimack Street, Lawrence, MA
 
01843
(Address of principal executive offices)
 
(Zip Code)

(978) 687-4700
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))








Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 21, 2014, Kevin Hershberger notified NxStage Medical, Inc. (“NxStage”) that he was resigning from his position as Vice President, Chief Accounting Officer and Controller, effective December 31, 2014 (the “Effective Date”), to accept a position as Chief Financial Officer with another company.

As of the Effective Date, Matthew W. Towse, 52, who has served as NxStage’s Senior Vice President and Chief Financial Officer since July 2013, will assume the duties of the principal accounting officer of NxStage. Mr. Towse's biographical information is incorporated herein by reference to NxStage's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2013.

 







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NxStage Medical, Inc.
 

By: /s/ Matthew W. Towse    
Matthew W. Towse
Chief Financial Officer    
Date: November 26, 2014